SEC Tracker
Get the app

Repligen RGEN

Repligen FY 2022: net income $186.0M, up 45%; diluted EPS $3.24

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Repligen reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income$186.0M+45% from $128.3M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS$3.24+45% from $2.24 in FY 202110-K income statement, on EDGAR
  3. Cash and cash equivalents$523.5M−13% from $603.8M in FY 202110-K balance sheet, on EDGAR
  4. Cash from operations$172.1M+45% from $119.0M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025